The future of these medications The weight loss medication landscape is evolving faster than at any point in pharmaceutical history
How it seems to work: it raises VEGF, the signal that grows new blood vessels
To balance risks and benefits, expert opinions emphasize the importance of individualized dosing, shared decision-making, and careful patient selection
By age 60, GHK-Cu levels in the body have fallen by roughly 60% a decline that correlates directly with the visible signs of skin aging: thinning, wrinkling, loss of firmness, slower healing
At the time of the switch, a subset of patients expressed concerns about the long-term impact that it would have on their condition management, and in an online survey many stated that they were dissatisfied with the level of care received
Athira Pharma's fosgonimeton (ATH-1017), part of the same HGF/c-Met program, failed the primary endpoint of its Phase 2/3 LIFT-AD Alzheimer's trial in September 2024